26th Jul 2011 07:01
26 July 2011
Source BioScience plc Source BioScience Wins Competitive Bid to Provide DNA Sequencing to Ireland's Leading Universities
Source BioScience plc , the international diagnostics and genetic analysis business serving the healthcare and research markets, has been selected by Trinity College Dublin ("TCD") and University College Dublin ("UCD") as a preferred supplier of DNA sequencing following a competitive tender process.
The terms of the Framework Agreement are to provide Ireland's two leading universities with DNA sequencing for two years, with an option to extend the contract for a further year. The contract is worth an expected minimum of £ 300,000 per year to the Company. This service will be delivered from its Dublin-based DNA sequencing laboratory, the only commercial sequencing laboratory of its kind in Ireland.
Source BioScience has a strong track record in the DNA sequencing field and has established itself as the leading commercial provider in the UK. The Company operates a network of laboratory facilities with operations in Oxford, Cambridge, London, Nottingham, Berlin and Dublin. These local facilities provide customers with immediate access to a high quality service that uses the latest research tools and laboratory practices to deliver the fastest DNA sequencing data.
Dr Nick Ash, CEO said: "Winning a place as a preferred provider is a real vote of confidence in Source BioScience's DNA sequencing services from TCD and UCD, the leading Universities in Ireland. We are confident that this endorsement will open up new opportunities in Ireland and will lead to further expansion of our Irish business."
--- ENDS ---
For further information, please contact:
Source BioScience plc Dr Nick Ash, CEO Tel: +44 (0) 115 973 9010 Email: [email protected] www.sourcebioscience.com College Hill (PR Agency to Source BioScience) Melanie Toyne Sewell/ Dimithri Wignarajah Tel: +44 (0)207 457 2020 Email: [email protected]
About Source BioScience:
Source BioScience plc is an international diagnostics and genetic analysis business serving the healthcare and research markets. Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. The PharmaBiotech division offers support for early stage therapeutic development, offering a 'one-stop shop' from tissue pathology, immunohistochemistry, sophisticated image analysis, biomarker determination and assay development to pharmacogenomics including genotyping and gene expression analysis. The Group has its headquarters in Nottingham, UK. Further information about Source BioScience can be found at www.sourcebioscience.com
XLONRelated Shares:
SBS.L